

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICATION</b> (Not for submission under 37 CFR 1.99) (Use several sheets if necessary)  Comparable to PTO/SI/08a (05-07)	Application Number:	10/556,224
	Filing Date:	September 27, 2006
	First Named Inventor:	Martin HENDRIX
	Art Unit:	1624
	Examiner Name:	Susanna MOORE
	Attorney Docket Number:	01-2116

U.S. PATENTS						
Examiner Initial*	Cite No.	Patent Number	Kind Code	Issue Date yyyy/mm/dd	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments
		3,732,225		1973/05/08	Breuer et al.	
		5,977,118		1999/11/02	Bacon et al.	
		5,656,629		1997/08/12	Bacon et al.	
		5,002,949		1991/03/26	Peseckis et al.	
		5,256,668		1993/10/26	Hsu et al.	

U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No.	Publication Number	Kind Code	Publication Date yyyy/mm/dd	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments
		2006/0111372	A1	2006/05/25	Hendrix et al.	
		2006/0106035	A1	2006/05/18	Hendrix et al.	
		2004/0266736	A1	2004/12/30	Wunder et al.	
		2006/0100222	A1	2006/05/11	Boss et al.	
		2007/0161662	A1	2007/07/12	Hendrix et al.	
		2007/0105876	A1	2007/05/10	Hendrix et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No.	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments	✓
		2 283 211	CA	A1	1998/09/17	Bayer Aktiengesellschaft	This patent appears to be an English language equivalent to WO 98/40384.	
		2 496 194	CA	A1	2004/03/04	Bayer Healthcare AG	This patent appears to be an English language equivalent to WO2004/018474.	
		2 496 292	CA	A1	2004/04/01	Bayer Healthcare AG	This patent appears to be an English language equivalent to WO2004/026286.	
		2 496 308	CA	A1	2004/04/01	Bayer Healthcare AG	This patent appears to be an English language equivalent to WO2004/026876.	

<sup>1</sup> √ indicates English Language translation is attached

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICATION</b> (Not for submission under 37 CFR 1.99) (Use several sheets if necessary)  Comparable to PTO/SB/08a (05-07)	Application Number:	10/556,224
	Filing Date:	September 27, 2006
	First Named Inventor:	Martin HENDRIX
	Art Unit:	1624
	Examiner Name:	Susanna MOORE
	Attorney Docket Number:	01-2116

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No.	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments	√ <sup>1</sup>
		2 438 890	CA	A1	2002/09/06	Bayer Aktiengesellschaft	This patent appears to be an English language equivalent to WO02/068423.	
		396 923	CH		1965/08/15	Ciba Limited		
		396 924	CH		1965/08/15	Ciba Limited		
		396 926	CH		1965/08/15	Ciba Limited		
		396 927	CH		1965/08/15	Ciba Limited		
		1 147 234	DE		1963/04/18	Ciba Limited		
		1 149 013	DE		1963/05/22	Ciba Limited		
		2 408 906	DE		1974/02/25	Chemische Fabrik von Heyden GmbH		
		1 156 415	DE		1963/10/31	Ciba Limited		
		101 56 249	DE	A1	2003/05/28	Bayer AG		
		1 153 023	DE		1963/08/22	Schmidt et al.		
		0 130 735	EP	A1	1985/01/09	American Home Products Corporation		
		0 995 751	EP	A2	2000/04/26	Pfizer Inc.		
		937726	GB		1963/09/25	Ciba Limited		
		973361	GB		1964/10/28	Ciba Limited		
		98/40384	WO	A1	1998/09/17	Bayer Aktiengesellschaft	CA2283211 cited herein appears to be an English language equivalent.	
		02/055082	WO	A1	2002/07/18	Vernalis Research Limited		
		03/041725	WO	A2	2003/05/22	Bayer Aktiengesellschaft	US2004/0266736 cited herein appears to be an English language equivalent	
		2004/026876	WO	A1	2004/04/01	Bayer Healthcare AG	CA2496308 cited herein appears to be an English language equivalent.	
		2004/026286	WO	A1	2004/04/01	Bayer Healthcare AG	CA2496292 cited herein appears to be an English language equivalent.	
		03/037899	WO	A1	2003/05/08	Pfizer Limited		
		02/068423	WO	A1	2002/09/06	Bayer Aktiengesellschaft	CA2438890 cited herein appears to be an English	

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICATION</b> (Not for submission under 37 CFR 1.99) (Use several sheets if necessary)  Comparable to PTO/SI/08a (05-07)	Application Number:	10/556,224
	Filing Date:	September 27, 2006
	First Named Inventor:	Martin HENDRIX
	Art Unit:	1624
	Examiner Name:	Susanna MOORE
	Attorney Docket Number:	01-2116

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No.	Foreign Document Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear or Relevant Comments	√ <sup>1</sup>
		02/06288	WO	A1	2002/01/24	F.Hoffmann-La Roche AG	language equivalent.	
		95/10506	WO	A1	1995/04/20	The Du Pont Pharmaceutical Company		
		00/18758	WO	A1	2000/04/06	Mitsubishi Chemical Corporation		
		02/098864	WO	A1	2002/12/12	F.Hoffmann-La Roche AG		
		99/41253	WO	A1	1999/08/19	Tularik Inc.		
		98/10765	WO	A1	1998/03/19	The Board of Trustees of the Leland Stanford Junior University		

NON-PATENT LITERATURE DOCUMENTS								
Examiner Initial*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages (s), volume-issue number(s), publisher, city and/or country where published.						√ <sup>2</sup>
		International Search Report for corresponding international application PCT/EP2004/004455 mailed September 17, 2004.						
		International Search Report for PCT/EP2004/006477 mailed October 27, 2004.						
		International Search Report for PCT/03/08923 mailed December 15, 2003.						
		International Search Report for PCT/EP03/08979 mailed November 25, 2003.						
		International Search Report for PCT/EP03/08880 mailed April 16, 2004.						
		International Search Report for PCT/EP2004/004412 mailed July 14, 2004.						
		International Search Report for PCT/EP2004/014872 mailed May 19, 2005.						
		JI-YE WEI, ET AL; Molecular and Pharmacological Analysis of Cyclic Nucleotide-Gated Channel Function in the Central Nervous System, Progress in Neurobiology (1998) vol. 56, pp. 37-64.						
		DOUGLAS A. FISHER, ET AL; Isolation and Characterization of PDESA, A Novel Human cGMP-specific Phosphodiesterase; Journal of Biological Chemistry (1998) vol. 273, no. 25, pp. 15559-1 5564.						
		MICHEL GUIPPONI, ET AL; Identification and Characterization of a Novel Cyclic Nucleotide Phosphodiesterase Gene (PDESA) That Maps to 21q22.3: Alternative Splicing of mRNA Transcripts,						

<sup>2</sup> √ indicates English Language translation is attached

<b>Examiner:</b>	<b>Date Considered:</b>
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICATION</b> (Not for submission under 37 CFR 1.99) (Use several sheets if necessary)  Comparable to PTO/SB/08a (05-07)	Application Number:	10/556,224
	Filing Date:	September 27, 2006
	First Named Inventor:	Martin HENDRIX
	Art Unit:	1624
	Examiner Name:	Susanna MOORE
	Attorney Docket Number:	01-2116

NON-PATENT LITERATURE DOCUMENTS		
	Genomic Structure and Sequence; Hum Genet (1998) vol. 103, pp. 386-392.	
	SCOTT H. SONDERLING, ET AL; Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry (1998) vol. 273, no. 25, pp. 15553-15558.	
	SVETLANA G. ANDREEVA, ET AL; Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain, Journal of Neuroscience (2001) vol. 21, no. 22, pp. 9068-9076.	
	TIMOTHY J. MARTINS, ET AL; Purification and Characterization of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphodiesterase from Bovine Tissues, Journal of Biological Chemistry (1982) vol. 257, no. 4, pp. 1973-1979.	
	SHARRON H. FRANCIS, ET AL; Characterization of a Novel cGMP Binding Protein from Rat Lung, Journal of Biological Chemistry (1980) vol. 255, no. 2, pp. 620-626.	
	PETER G. GILLESPIE, ET AL; Characterization of a Bovine Cone Photoreceptor Phosphodiesterase Purified by Cyclic GMP-Sepharose Chromatography; Journal of Biological Chemistry (1988) vol. 263, no. 17, pp. 8133-8141.	
	LINDSAY FAWCETT, ET AL; Molecular Cloning and Characterization of a Distinct Human Phosphodiesterase Gene Family: PDE11A; Proc. Natl. Acad. Sci. (2000) vol. 97, no. 7, pp. 3702-3707.	
	SEIKO MURASHIMA, ET AL; Characterization of Particulate Cyclic Nucleotide Phosphodiesterases from Bovine Brain: Purification of a Distinct cGMP-Stimulated Isoenzyme; Biochemistry (1990) vol. 29, no. 22, pp. 5285-5292.	
	SCOTT H. SONDERLING, ET AL; Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions; Current Opinion in Cell Biology (2000) vol. 12, pp. 174-179.	
	AKIRA MIYASHITA, ET AL; Studies on Pyrazolo[3,4-d]Pyrimidine Derivatives. XVIII. Facile Preparation of 1H-Pyrazolo[3,4-d]Pyrimidin-4(5H)-Ones; Heterocycles (1990) vol. 31, no. 7, p. 1309-1314.	
	KATE LOUGHNEY, ET AL; Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3',5'-Cyclic Nucleotide Phosphodiesterases, Journal of Biological Chemistry (1996) vol. 271, no. 2, pp. 796-806.	
	GUY J. ROSMAN, ET AL; Isolation and Characterization of Human cDNAs encoding a cGMP-stimulated 3',5'-Cyclic Nucleotide Phosphodiesterase; Gene (1997) vol. 191, pp. 89-95.	
	TAKASHI MIKI, ET AL; Characterization of the cDNA and Gene Encoding Human PDE3B, the cGIP1 Isoform of the Human Cyclic GMP-Inhibited Cyclic Nucleotide Phosphodiesterase Family; Genomics (1996) vol. 36, pp. 476-485.	
	RENA OBERNOLTE, ET AL; The cDNA of a Human Lymphocyte cyclic-AMP Phosphodiesterase (PDE IV) Reveals a Multigene Family; Gene (1993) vol. 129, pp. 239-247.	
	KATE LOUGHNEY, ET AL; Isolation and Characterization of cDNAs encoding PDESA, a Human cGMP-Binding, cGMP-Specific Y.9-Cyclic Nucleotide Phosphodiesterase; Gene (1998) vol. 216, pp. 139-147.	
	J. M. HETMAN, ET AL; Cloning and Characterization of PDE7B, a cAMP-specific Phosphodiesterase, Proc. Natl. Acad. Sci. (2000) vol. 97, no. 1, pp. 472-476.	
	DOUGLAS A. FISHER, ET AL; Isolation and Characterization of PDEM, a Novel Human cAMP-Specific Phosphodiesterase; Biochemical and Biophysical Research Communications (1998) vol. 246, pp. 570-577.	
	KOTOMI FUJISHIGE, ET AL; Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes R21 Both cAMP and cGMP (PDEIOA); Journal of Biological Chemistry (1999) vol. 274, no. 26, pp. 18438-18445.	

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICATION</b> (Not for submission under 37 CFR 1.99) (Use several sheets if necessary)  Comparable to PTO/SB/08a (05-07)	Application Number:	10/556,224
	Filing Date:	September 27, 2006
	First Named Inventor:	Martin HENDRIX
	Art Unit:	1624
	Examiner Name:	Susanna MOORE
	Attorney Docket Number:	01-2116

NON-PATENT LITERATURE DOCUMENTS			
		JAMES E. HUETTNER, ET AL; Primary Culture of Identified Neurons from the Visual Cortex of Postnatal Rats; Journal of Neuroscience (1986) vol. 6, pp. 3044-3060.	
		MAGNUS ROENN, ET AL; Palladium (II)-Catalyzed Cyclization Using Molecular Oxygen as Reoxidant; Tetrahedron Letters (1995) vol. 36, no. 42, pp. 7749-7752.	
		HIEKE GIELEN, ET AL; A Novel Approach to Amidines from Esters; Tetrahedron Letters (2002) vol. 43 pages 419-421.	
		K. HEMENDER REDDY, ET AL; Versatile Synthesis of 6-Alkyl/Aryl-1H-Pyrazolo[3,4-d]Pyrimidin-4[5H]-Ones; Indian Journal of Chemistry (1992) vol. 31B, pages 163-166.	
		ARNE SCHOUSBOE, ET AL; Role of Ca++ and Other Second Messengers in Excitatory Amino Acid Receptor Mediated Neurogeneration: Clinical Perspective; Clinical Neuroscience (1997) vol. 4, pages 194-198.	
		Accessed on March 18, 2007. <a href="http://www.mcmentalhealth.org.uk/information/mcmental-health-a-z/dementia/">http://www.mcmentalhealth.org.uk/information/mcmental-health-a-z/dementia/</a>	
		SUDHA R. VIPPAGUNTA, ET AL; Crystalline Solids; Advanced Drug Delivery Reviews (2001) vol. 48 pages 3-26.	
		ANTHONY R. WEST; Solid Solutions; John Wiley & Sons, chapter 10 pages 358 and 365 (1988).	
		JOACHIM ULRICH; Crystallization: 4. Crystal Characteristics; Kirk-Othmer Encyclopedia of Chemical Technology; August 2002.	
		CLAIRE LUGNIER; Cyclic Nucleotide Phosphodiesterase (PDE) Superfamily: A New Target for the Development of Specific Therapeutic Agents; Pharmacology & Therapeutics (2006) vol. 109 pages 366-398.	
		JEHAN BAGLI, ET AL; Chemistry and Positive Inotropic Effect of Pelrinone and related Derivates. A Novel Class of 2-Methylpyrimidones as Inotropic Agents; Journal of Medicinal Chemistry (1988) vol. 31 pages 814-823.	
		RUDOLF GOMPPER, ET AL; Substituted Dithiocarboxylic Acids and Ketene Thioacetals; Institute for Organic Chemistry Technology (1962) vol. 95, pages 2861-2870. German & English Translation.	
		P. SCHMIDT, ET AL; A New Synthesis of Pyrazolo[3,4-d]Pyrimidines Having Coronary Dilation Properties; Helvetica Chimica Acta (1962) vol. XLV, no. 189, pages 1620- 1627. German & English Translation	

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	